Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again [Seeking Alpha]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Seeking Alpha
Summary Shares of Acadia trended lower this year due to Daybue's poor quarterly sales performance, and also due to Nuplazid's failure in the phase 3 trial in schizophrenia patients. The full-year guidance on Daybue was reduced as Acadia is finding fewer new patients, not because of higher patient churn. With most of the headwinds in the rearview mirror, I expect better performance of Daybue going forward. Nuplazid's strong performance remained largely unnoticed given the investor focus on Daybue. Other key pipeline projects are on track with ACP-204, and ACP-101 progressing in phase 2/3 and phase 3 trials, respectively. Spencer Platt/Getty Images News ACADIA Pharmaceuticals Inc.'s NASDAQ: ACAD ) stock has underperformed significantly this year as investor concerns about Daybue's uptake persist, and Nuplazid's failure in the phase 3 trial as adjunctive treatment of schizophrenia was another contributing factor. I Recommended For You About ACAD Stock
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Acadia Pharmaceuticals to Participate at Upcoming Investor ConferencesBusiness Wire
- Ryan Reynolds on his 'complicated' relationship with his dad, how it's changed him [USA TODAY]USA TODAY
- Ryan Reynolds Announces More to Parkinson’s® CampaignBusiness Wire
ACAD
Earnings
- 8/6/24 - Beat
ACAD
Sec Filings
- 8/20/24 - Form 4
- 8/20/24 - Form 4
- 8/20/24 - Form 4
- ACAD's page on the SEC website